🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

'Pharma bro' Shkreli to be held responsible for $10.4 million in losses: U.S. judge

Published 02/26/2018, 01:04 PM
© Reuters. FILE PHOTO: Martin Shkreli arrives for his trial at US Federal Court in Brooklyn New York
META
-
TVTX
-

By Brendan Pierson

NEW YORK (Reuters) - Former U.S. drug company executive Martin Shkreli will be held responsible for $10.4 million in financial losses when he is sentenced for defrauding investors, a federal judge ruled on Monday, rejecting his argument that he did not cause any losses because his investors eventually came out ahead.

The ruling from U.S. District Judge Kiyo Matsumoto could mean more prison time for Shkreli, since the amount of financial loss plays a major role in federal sentencing guidelines. While Matsumoto must consider the guidelines at the sentencing, which is scheduled for March 9, she is not bound to follow them.

Benjamin Brafman, a lawyer for Shkreli, said in an email that he was "disappointed by the ruling but still hopeful that the court will find it in her heart to impose a reasonably lenient sentence."

A spokesman for the prosecutors declined to comment.

Shkreli, 34, became famous as the "Pharma Bro" after raising the price of anti-infection drug Daraprim by over 5,000 percent in 2015 while he was chief executive of Turing Pharmaceuticals. He was found guilty by a jury in August of unrelated securities fraud charges brought against him in December 2015.

Shkreli has been in jail since September, when Matsumoto revoked his bail after he offered a $5,000 bounty for a strand of Hillary Clinton's hair in a Facebook (NASDAQ:FB) post.

He was convicted of lying to investors about the performance of two hedge funds he controlled, MSMB Capital and MSMB Healthcare, and of conspiring to manipulate the stock price of a pharmaceutical company he founded, Retrophin Inc (O:RTRX).

Prosecutors have not disputed that Shkreli's investors came out ahead after Shkreli paid them in shares of Retrophin, and in some cases through settlement agreements and consulting contracts with the company. Shkreli's lawyers argued that as a result, he should not be held responsible for financial loss.

Matsumoto said in Monday's order that under federal law, all of the money that investors put in Shkreli's funds as a result of his fraud, about $6.4 million, must be considered loss. She also said he should get no credit for paying investors back because he only did so after they became suspicious.

© Reuters. FILE PHOTO: Martin Shkreli arrives for his trial at US Federal Court in Brooklyn New York

The judge said that Shkreli should be held responsible for about $4 million in intended loss to investors for trying to prop up the price of Retrophin shares by trying to stop a group of investors from selling them, even though he was not fully successful.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.